Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

664 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction.
Belluomini L, Dionisi V, Palmerio S, Vincenzi S, Avancini A, Casali M, Riva ST, Menis J, Mazzarotto R, Pilotto S, Milella M. Belluomini L, et al. Among authors: milella m. Clin Lung Cancer. 2022 May;23(3):e269-e272. doi: 10.1016/j.cllc.2021.07.004. Epub 2021 Jul 20. Clin Lung Cancer. 2022. PMID: 34470722 Clinical Trial.
Maintenance therapy in NSCLC: why? To whom? Which agent?
Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E. Novello S, et al. Among authors: milella m. J Exp Clin Cancer Res. 2011 May 6;30(1):50. doi: 10.1186/1756-9966-30-50. J Exp Clin Cancer Res. 2011. PMID: 21548925 Free PMC article. Review.
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E. Pilotto S, et al. Among authors: milella m. Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472711 Review.
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M. Vari S, et al. Among authors: milella m. Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3. Expert Opin Drug Discov. 2013. PMID: 24088065 Review.
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE Study Team. de Marinis F, et al. Clin Lung Cancer. 2014 Sep;15(5):338-45.e1. doi: 10.1016/j.cllc.2014.04.004. Epub 2014 May 14. Clin Lung Cancer. 2014. PMID: 24925809 Free article.
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.
Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. Bria E, et al. Among authors: milella m. Crit Rev Oncol Hematol. 2015 Jan;93(1):50-9. doi: 10.1016/j.critrevonc.2014.08.001. Epub 2014 Aug 18. Crit Rev Oncol Hematol. 2015. PMID: 25195095 Review.
664 results